Incretin-based therapies in type 2 diabetes: A review of clinical results

被引：20

作者：

Bosi, Emanuele ^{[1
]}

Lucotti, Pietro

Setola, Emanuela

Monti, Lucilla

Piatti, Pier Marco

机构：

[1] Ist Sci San Raffaele, Diabet & Endocrinol Unit, Dept Internal Med, I-20132 Milan, Italy

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2008年 / 82卷

关键词：

GLP-1; analogues; DPP-4; inhibitors; Exenatide; Sitagliptin; Vidagliptin; Diabetes mellitus;

D O I：

10.1016/j.diabres.2008.10.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

GLP-1 analogues (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) represent new classes of anti-diabetic agents for the treatment of type 2 diabetes. The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Efficacy was demonstrated in terms of reduction of HbA1c, fasting and postprandial glucose. Moreover, exenatide showed a favourable effect on weight, while DPP-4 inhibitors were neutral with respect to this outcome. The low rate of hypoglycemic events seen in all studies confirms the glucose dependent action of incretins. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：S102 / S107

页数：6

共 65 条

[1] Fasting hyperglycemia impairs glucose- but not insulin-mediated suppression of glucagon secretion [J].

Abdul-Ghani, Muhammad ;

DeFronzo, Ralph A. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (05) :1778-1784

[2] Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes [J].

Ahrén, B ;

Gomis, R ;

Standl, E ;

Mills, D ;

Schweizer, A .

DIABETES CARE, 2004, 27 (12) :2874-2880

[3] Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis [J].

Amori, Renee E. ;

Lau, Joseph ;

Pittas, Anastassios G. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02) :194-206

[4]

[Anonymous], 1995, Diabetes, V44, P1249

[5] Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [J].

Aschner, Pablo ;

Kipnes, Mark S. ;

Lunceford, Jared K. ;

Sanchez, Matilde ;

Mickel, Carolyn ;

Williams-Herman, Debora E. .

DIABETES CARE, 2006, 29 (12) :2632-2637

[6] Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [J].

Augeri, DJ ;

Robl, JA ;

Betebenner, DA ;

Magnin, DR ;

Khanna, A ;

Robertson, JG ;

Wang, AY ;

Simpkins, LM ;

Taunk, P ;

Huang, Q ;

Han, SP ;

Abboa-Offei, B ;

Cap, M ;

Xin, L ;

Tao, L ;

Tozzo, E ;

Welzel, GE ;

Egan, DM ;

Marcinkeviciene, J ;

Chang, SY ;

Biller, SA ;

Kirby, MS ;

Parker, RA ;

Hamann, LG .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (15) :5025-5037

[7] Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study [J].

Bolli, G. ;

Dotta, F. ;

Rochotte, E. ;

Cohen, S. E. .

DIABETES OBESITY & METABOLISM, 2008, 10 (01) :82-90

[8] Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin [J].

Bosi, Emanuele ;

Camisasca, Riccardo Paolo ;

Collober, Carole ;

Rochotte, Erika ;

Garber, Alan J. .

DIABETES CARE, 2007, 30 (04) :890-895

[9] Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes [J].

Buse, JB ;

Henry, RR ;

Han, J ;

Kim, DD ;

Fineman, MS ;

Baron, AD .

DIABETES CARE, 2004, 27 (11) :2628-2635

[10] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [J].

Charbonnel, Bernard ;

Karasik, Avraham ;

Liu, Ji ;

Wu, Mei ;

Meininger, Gary .

DIABETES CARE, 2006, 29 (12) :2638-2643

← 1 2 3 4 5 6 7 →